PHOENIX—Although biosimilars have been available for infliximab (Remicade, Janssen) for approximately five years, uptake across the country has been slow, partly due to provider hesitancy, according to researchers at Rhode Island Hospital, in Providence. But by adding pharmacists into the management mix, use of biosimilars can be significantly increased, they reported at the 2022 ASHP Summer Meetings and Exhibition (poster 41M).
Specifically, patients who were managed by a